Laboratory of Malaria, Centro de Pesquisa Rene Rachou/Fiocruz, Belo Horizonte, Brazil.
PLoS One. 2011;6(8):e22944. doi: 10.1371/journal.pone.0022944. Epub 2011 Aug 2.
The dependence of Plasmodium vivax on invasion mediated by Duffy binding protein (DBP) makes this protein a prime candidate for development of a vaccine. However, the development of a DBP-based vaccine might be hampered by the high variability of the protein ligand (DBP(II)), known to bias the immune response toward a specific DBP variant. Here, the hypothesis being investigated is that the analysis of the worldwide DBP(II) sequences will allow us to determine the minimum number of haplotypes (MNH) to be included in a DBP-based vaccine of broad coverage. For that, all DBP(II) sequences available were compiled and MNH was based on the most frequent nonsynonymous single nucleotide polymorphisms, the majority mapped on B and T cell epitopes. A preliminary analysis of DBP(II) genetic diversity from eight malaria-endemic countries estimated that a number between two to six DBP haplotypes (17 in total) would target at least 50% of parasite population circulating in each endemic region. Aiming to avoid region-specific haplotypes, we next analyzed the MNH that broadly cover worldwide parasite population. The results demonstrated that seven haplotypes would be required to cover around 60% of DBP(II) sequences available. Trying to validate these selected haplotypes per country, we found that five out of the eight countries will be covered by the MNH (67% of parasite populations, range 48-84%). In addition, to identify related subgroups of DBP(II) sequences we used a Bayesian clustering algorithm. The algorithm grouped all DBP(II) sequences in six populations that were independent of geographic origin, with ancestral populations present in different proportions in each country. In conclusion, in this first attempt to undertake a global analysis about DBP(II) variability, the results suggest that the development of DBP-based vaccine should consider multi-haplotype strategies; otherwise a putative P. vivax vaccine may not target some parasite populations.
间日疟原虫对 Duffy 结合蛋白(DBP)介导的入侵的依赖性使得该蛋白成为疫苗开发的首选候选物。然而,由于蛋白配体(DBP(II))的高度变异性,可能会阻碍基于 DBP 的疫苗的开发,这种变异性已知会使免疫反应偏向于特定的 DBP 变体。在这里,我们正在研究的假设是,对全球范围内的 DBP(II)序列进行分析,将使我们能够确定在具有广泛覆盖范围的基于 DBP 的疫苗中需要包含的最小单倍型数(MNH)。为此,我们编译了所有可用的 DBP(II)序列,并根据最常见的非同义单核苷酸多态性(大多数位于 B 和 T 细胞表位上)来确定 MNH。对来自 8 个疟疾流行国家的 DBP(II)遗传多样性的初步分析估计,在每个流行地区,大约有 2 到 6 种 DBP 单倍型(总共 17 种)将针对至少 50%的寄生虫种群。为了避免针对特定区域的单倍型,我们接下来分析了广泛覆盖全球寄生虫种群的 MNH。结果表明,需要 7 种单倍型来覆盖大约 60%的可用 DBP(II)序列。尝试根据每个国家验证这些选定的单倍型,我们发现 8 个国家中有 5 个国家(67%的寄生虫种群,范围为 48-84%)将被 MNH 覆盖。此外,为了识别 DBP(II)序列的相关亚群,我们使用了贝叶斯聚类算法。该算法将所有 DBP(II)序列分为 6 个种群,这些种群与地理起源无关,每个国家的祖先种群比例不同。总之,在首次尝试对 DBP(II)变异性进行全球分析时,结果表明,基于 DBP 的疫苗的开发应考虑多单倍型策略;否则,潜在的间日疟原虫疫苗可能无法针对某些寄生虫种群。